CMS Physician Fee Schedule
The published Medicare rates and payment rules behind most of the codes on this page.
Oncology billing services hinge on the chemotherapy administration hierarchy (96413-96416), J-code drug waste reporting with the JW modifier, and hydration 96360/96361 bundling rules. Add modifier 25 with infusion-plus-E/M visits and 90-day global periods on oncologic surgery, and general billers miss revenue on every encounter. MedFactor delivers hem-onc-specific RCM that protects every claim.
Request Free Billing Audit
Explore Our Services
HIPAA Compliant
AAPC Certified Coders
Nationwide Support
Hem-Onc Specialists
Chemo Administration LadderLive
1Chemo IV infusion, first hourInitial substance — base code96413
+Each additional hourAdd-on per hour after first96415
+Prolonged infusion >8 hrExtended-duration chemo96416
+Intralesional chemoUp to 7 lesions / each addl96405 / 96406
HHydration (non-chemo)Separately reportable w/ supportive documentation96360 / 96361
JWJ-code drug wasteDiscarded amount — separately reportableJW
0%Clean Claim Rate
0%Denial Reduction
0dDays in A/R
From medical oncology and infusion centers to benign hematology and cellular therapy, we tailor billing to the coding rules of every hematology and oncology subspecialty.
Medical Oncology
Chemotherapy administration hierarchy (96413-96416), J-code drug capture, and JW modifier waste reporting for IV, prolonged, and intralesional infusion.
Hematology / Benign
Anemia (D50-D64), coagulation disorders (D65-D69), myelodysplastic syndromes, and therapeutic phlebotomy with diagnosis-driven medical necessity.
Solid Tumors
Oncologic resection with 90-day global period tracking, modifier 58 staged procedures, and assistant surgeon modifier 80/82 where appropriate.
Infusion Center
Hydration 96360/96361 with supportive documentation, sequential infusion 96417, and non-chemo therapeutic 96365/96366 bundling accuracy.
BMT / Cellular Therapy
Bone marrow transplant cell harvesting and infusion, CAR-T cell therapy codes, and high-cost drug administration with rigorous prior authorization.
Clinical Trials
Clinical trial Q0/Q1 modifiers, investigational vs routine service separation, and sponsor-billed items carved out of standard claim submission.
Chemotherapy is billed as a base infusion code plus add-on codes for each additional hour and sequential substance — and separately reportable items like hydration and discarded drug (JW modifier) must be captured or revenue is lost. This is the largest source of hem-onc revenue leakage.
One chemo session bills a first-hour base code, adds each additional hour, then separately reports hydration, sequential substances, and J-code drug waste with the JW modifier.
Base ProcedureChemo IV infusion, first hour (initial substance)96413
Each additional hour of infusionAdd-on per hour after the first96415
Prolonged infusion >8 hoursExtended-duration chemotherapy96416
Sequential different substance, up to 1 hrEach additional chemo agent, same session96417
Intralesional chemo (up to 7 lesions / each addl)Intralesional administration96405 / 96406
Hydration (non-chemo) — separately reportable96360 initial + 96361 each addl hour, with supportive documentation96360 / 96361
J-code drug waste (JW modifier)Discarded amount from a single-dose vial — separately reportableJW
Our focus: We sequence 96413 as the first-hour base, add 96415 for each additional hour and 96417 for each sequential substance, separately report hydration 96360/96361 with supportive documentation, and report discarded single-use vial drug with the JW modifier — preventing the most common hem-onc revenue leaks while capturing every legitimately separate component of an infusion encounter. The 90-day global on certain oncologic surgical procedures is tracked so post-operative E/M and ancillary services are billed correctly.
Hem-onc billing is governed by the chemo administration hierarchy, J-code waste rules, and clinical trial modifiers that general billing companies cannot navigate effectively.
Add-on hours (96415), prolonged infusion (96416), and sequential substances (96417) dropped or bundled under the 96413 base, losing per-hour revenue.
Severity
Discarded drug from single-use vials not reported with the JW modifier, and J-code drug units mis-reported, losing high-cost drug revenue.
Severity
Hydration denied as bundled into chemo infusion when billed without supportive documentation or correct sequencing of the hydration start/stop times.
Severity
Same-day E/M with infusion denied as bundled when modifier 25 is not appended with documented separate, significant visit reason.
Severity
Clinical trial services billed without Q0 (investigational) or Q1 (routine) modifiers, causing denials or sponsor-payment misallocation.
Severity
Post-operative E/M, ancillary services, and complications denied inside the 90-day global on oncologic surgical procedures when billed without modifier 24/25/79.
Severity
Quick reference for the most frequently used codes in hematology and oncology billing and coding.
CPT / HCPCS
ICD-10 Codes
Modifiers
| Code | Description | Common Use |
|---|---|---|
| 96413 | Chemo admin, IV infusion, up to 1 hr, initial substance | First-hour base chemo code |
| 96415 | Chemo admin, IV infusion, each additional hour | Hourly add-on to 96413 |
| 96416 | Chemo admin, IV infusion, >8 hours | Prolonged-infusion chemo |
| 96417 | Chemo admin, each additional sequential substance, up to 1 hr | Second agent same session |
| 96405 | Chemo admin, intralesional, up to 7 lesions | Intralesional chemo |
| 96406 | Chemo admin, intralesional, each additional lesion | Addl lesion intralesional |
| 96360 | Hydration IV infusion, initial 31 min–1 hr | Non-chemo hydration base |
| 96361 | Hydration IV infusion, each additional hour | Hydration add-on |
| 96365 | Therapeutic/diagnostic IV infusion, up to 1 hr (non-chemo) | Non-chemo infusion base |
| 96366 | Therapeutic/diagnostic IV infusion, each addl hr (non-chemo) | Non-chemo infusion add-on |
| J9035 | Bevacizumab injection, 10 mg | Anti-VEGF monoclonal antibody |
| J9171 | Docetaxel injection, 1 mg | Taxane chemotherapy |
| J9000 | Doxorubicin HCl injection, 10 mg | Anthracycline chemotherapy |
| J9206 | Irinotecan injection, 20 mg | Topoisomerase inhibitor |
| J9355 | Trastuzumab injection, 10 mg (excludes biosimilar) | HER2 monoclonal antibody |
| Code | Description | Clinical Context |
|---|---|---|
| C00-C96 | Malignant neoplasms | Chapter-range solid & hematologic malignancy |
| C50.- | Malignant neoplasm of breast | Breast cancer systemic therapy |
| C34.- | Malignant neoplasm of bronchus/lung | Lung cancer therapy |
| C61 | Malignant neoplasm of prostate | Prostate oncology treatment |
| C81-C96 | Lymphoid/leukemic malignancies | Lymphoma & leukemia coding |
| D45-D49 | Neoplasms of uncertain/unspecified behavior | Myelodysplastic & uncertain hematologic |
| D50-D64 | Anemias | Benign hematology / chemo-induced anemia |
| D65-D69 | Coagulation & hemorrhagic disorders | Coagulopathy management |
| Z51.11 | Encounter for antineoplastic chemotherapy | Chemo encounter status |
| Z51.12 | Encounter for antineoplastic radiation therapy | Radiation encounter status |
| Z12.x | Encounter for screening for neoplasm | Screening / preventive oncology |
| Modifier | Description | Hem-Onc Application |
|---|---|---|
| 25 | Significant, separately identifiable E/M same day | E/M with same-day chemo infusion / hydration |
| 59 | Distinct procedural service | Distinct infusion / injection services same session |
| 51 | Multiple procedures | Multiple same-session procedures |
| 22 | Increased procedural service | Unusually complex infusion / procedure |
| 52 | Reduced services | Partially discontinued infusion / procedure |
| JW | Drug amount discarded / not administered | Single-use vial J-code waste reporting |
| Q0 | Investigational clinical service | Clinical trial investigational item |
| Q1 | Routine clinical service in clinical trial | Clinical trial routine-cost item |
Comprehensive revenue cycle management designed specifically for hematology and oncology practices.
Specialty coders handle the chemo admin hierarchy (96413-96416), J-code capture, JW waste, hydration sequencing, and clinical trial Q0/Q1 with accuracy.
Chemo admin hierarchy defense, J-code waste corrections, and appeals with infusion documentation for hem-onc denials.
Pre-administration authorization for chemotherapy agents, biologics, CAR-T therapy, and clinical trial regimens.
Prioritized follow-up on aged chemo, J-code, and infusion claims with strategic payer escalation to maximize recovery.
Regular audits focused on chemo admin capture, JW waste reporting, modifier 25 with infusion, and clinical trial Q0/Q1 accuracy.
Real-time dashboards tracking infusion volume, J-code drug spend, and per-physician productivity.
Understanding the most common denial reasons is the first step to preventing them on chemo, infusion, and surgical oncology claims.
Additional infusion hours (96415), prolonged infusion (96416), and sequential substances (96417) dropped or denied as bundled under the 96413 base.
Correct sequencing of 96413 base plus 96415/96416/96417 add-ons with start/stop time documentation.
Discarded single-use vial drug not reported with JW modifier, and J-code units misreported, losing high-cost drug revenue.
Accurate J-code unit calculation and JW modifier reporting for all discarded drug amounts.
Hydration 96360/96361 denied as bundled into chemotherapy infusion when billed without supportive documentation and correct start/stop sequencing.
Separately reportable hydration with documented medical necessity and proper time sequencing.
Same-day E/M with infusion denied as bundled when modifier 25 is not appended with documented separate visit reason.
Modifier 25 on same-day E/M with documented separate, significant visit reason.
Identifying and plugging these common revenue leakage points can significantly improve your practice’s bottom line.
Additional infusion hours and sequential substances not billed as add-ons to the 96413 base.
Discarded single-use vial drug never reported with the JW modifier, losing per-unit drug revenue.
Hydration 96360/96361 bundled into chemo and never separately reported with supportive documentation.
Clinical trial services billed without Q0/Q1 modifiers, causing denials and sponsor-payment misallocation.
See how hem-onc-specific revenue cycle management transforms your practice’s financial performance.
A structured onboarding process designed to deliver measurable improvements within the first 90 days.
1WEEK 1–2
Review of hem-onc billing operations, chemo admin capture, J-code waste reporting, and revenue cycle baseline.
2WEEK 3–4
EMR and infusion-system integration, dedicated hem-onc billing team, and payer enrollment verification.
3WEEK 5–8
Full billing with real-time claim submission, modifier verification, and denial prevention protocols.
4WEEK 9–12
Performance review against baseline, workflow optimization, and documented revenue improvement.
How our hem-onc-specific approach compares to in-house billing and general medical billing companies.
| Capability | In-House Team | General Billing Co. | MedFactor Hem-Onc |
|---|---|---|---|
| Chemo admin 96413-96416 add-on capture | Inconsistent | ✕ | ✓ |
| Sequential substance 96417 capture | ✕ | ✕ | ✓ |
| J-code drug waste (JW modifier) | Inconsistent | ✕ | ✓ |
| Hydration 96360/96361 separate reporting | ✕ | ✕ | ✓ |
| Modifier 25 with infusion + E/M | Inconsistent | Partial | ✓ |
| Clinical trial Q0/Q1 modifier tracking | Manual | Partial | ✓ |
| 90-day global period tracking on oncologic surgery | Manual | Partial | ✓ |
| Chemo admin capture reporting | ✕ | ✕ | ✓ |
| Dedicated hem-onc billing team | ✕ | ✕ | ✓ |
Our team combines deep hematology and oncology billing expertise with the technology and processes to deliver consistent, measurable results for infusion centers, medical oncology, and benign hematology practices.
Discover exactly where your hematology and oncology practice is losing revenue. Our no-obligation audit analyzes your chemo admin capture, J-code waste reporting, and modifier compliance.
Schedule Your Free Audit
24%Average Revenue ImprovementPractices see an average 24% improvement in net collections within the first year.
2 WeeksAudit Completion TimeComplete billing and coding audit delivered within 10 business days.
Real results from hematology and oncology practices that partnered with MedFactor for specialty revenue cycle management.
$1.2MRevenue Recovered
Infusion / Oncology Center
A hospital-based infusion center was dropping additional infusion hours and sequential substances under the 96413 base and never reporting JW waste. MedFactor implemented correct add-on sequencing and JW reporting, recovering substantial infusion revenue in nine months.
46%Denial Reduction19dA/R Reduced
$310KAnnual Capture
Hematology / Benign
A benign hematology clinic was under-capturing anemia (D50-D64) and coagulation disorder diagnoses and bundling hydration. MedFactor implemented diagnosis-driven medical necessity and separate hydration reporting, recovering infusion and E/M revenue.
$310KAnnual Recovery31%Revenue Increase
+27%Revenue Increase
Clinical Trials Group
A clinical-trials-heavy oncology group was billing investigational and routine services without Q0/Q1 modifiers and misallocating sponsor-billed items. MedFactor implemented trial-modifier protocols that protected routine-cost revenue and sponsor billing.
$240KAnnual Savings27%Revenue Increase
No matter where your hematology and oncology practice operates, our team understands the payer landscape and regulatory requirements in your region.
Deep coding knowledge across Medicare, Medicaid, and commercial payers for chemotherapy and infusion services.
High-cost drug coverage and J-code/JW waste rules applied correctly across all 50 states.
Facility and professional billing coordination across hospital-based infusion and office-based chemo administration.
State-by-state clinical trial coverage and Q0/Q1 modifier compliance for research-active oncology groups.
Common questions from hematology and oncology practices considering MedFactor’s specialty RCM services.
How does the chemotherapy administration hierarchy 96413-96416 work?
Chemotherapy IV infusion is billed as a base first-hour code plus add-on codes. 96413 is the initial substance, first hour. Each additional hour of that same infusion is billed with 96415. Prolonged infusions lasting more than 8 hours use 96416, and each additional sequential different substance given in the same session uses 96417 (up to one hour). The highest-valued chemo drug is sequenced first to maximize payment, and each add-on must be documented with start/stop times. We capture every additional hour and sequential substance as the correct add-on rather than bundling them under the 96413 base, which is the most common way chemo admin revenue is lost.
What is the JW modifier and when is J-code drug waste reported?
The JW modifier is used to report the amount of a drug from a single-use vial or unit-dose package that is discarded and not administered to the patient. When a patient’s dose requires only part of a vial, the discarded amount is billed on a separate line with the JW modifier so the practice is paid for the full vial. Medicare requires JW reporting for discarded single-use vial drugs, and accurate J-code unit reporting (billing the correct number of units for the dose given plus the discarded amount) is essential.
We report JW on every applicable discarded dose so high-cost drug revenue is not lost, and we verify J-code units per payer rules before submission.
How is hydration 96360/96361 billed with chemotherapy?
Hydration (96360 for the initial 31 minutes through one hour, 96361 for each additional hour) is a non-chemo service that is separately reportable when it is medically necessary and supported by documentation. To bill hydration separately with chemotherapy, the hydration must have its own start/stop times, run before or after the chemo (not concurrently), and have a medical-necessity reason such as pre/post chemo hydration. Payers deny hydration bundled into the chemo infusion when start/stop times overlap or when no separate supportive documentation exists. We document and sequence hydration so it is paid rather than denied as inclusive to the chemotherapy administration.
When is modifier 25 used with an infusion and E/M visit?
When a significant, separately identifiable evaluation and management (E/M) visit occurs on the same day as a chemotherapy or hydration infusion, modifier 25 is appended to the E/M code to indicate the visit was distinct from the infusion service. The medical record must document a separate reason for the visit beyond routine infusion assessment — for example, a new symptom, change in treatment plan, or separate clinical decision. Without modifier 25, the E/M is denied as bundled into the infusion. We apply modifier 25 with documented separate visit reasons so same-day E/M with infusion is paid rather than denied as inclusive.
How do clinical trial Q0 and Q1 modifiers work?
Clinical trial services use two HCPCS modifiers: Q0 indicates an investigational clinical service furnished in a clinical research study (the item is typically not paid by Medicare and is billed to the sponsor); Q1 indicates a routine clinical service furnished in a clinical trial that Medicare does cover. Correct Q0/Q1 assignment determines who pays — Medicare or the trial sponsor — and misassignment causes denials, sponsor-payment misallocation, and compliance exposure. We identify which services are investigational (Q0, sponsor-billed) versus routine (Q1, Medicare-billed) per the trial protocol and CMS clinical trial policies, and apply the correct modifier on every line item.
How does the 90-day global period affect oncologic surgery billing?
Many oncologic surgical procedures carry a 90-day global period during which routine post-operative care is bundled into the surgical payment and not separately billable. Within that 90-day window, unrelated E/M visits may be billed with modifier 24 (unrelated E/M during a postoperative period) or modifier 25 if a significant separate service is performed, and staged or related procedures may use modifier 58. Without tracking the global period start date, post-operative services are denied as inclusive. We track every oncologic surgery global period and apply modifier 24/25/58/79 appropriately so unrelated post-operative care and staged procedures are paid rather than denied as bundled.
MedFactor applies the same code-level precision across the full practice spectrum. See how we bill these related specialties.
Radiation Oncology
Gynecologic Oncology
Rheumatology
All Specialties →
CPT®, ICD-10, HCPCS, and modifier codes referenced on this page reflect the current code sets and are subject to annual updates — always verify against the current-year fee schedule before submission. J-code descriptions, drug strengths, and coverage indicators change periodically; verify each J-code against the current CMS HCPCS file before billing. KPIs and case-study figures shown are representative benchmarks, not guarantees of individual practice results.
The rules on this page are published somewhere official. These are the ones worth reading yourself.
The published Medicare rates and payment rules behind most of the codes on this page.
The rules governing referrals between a practice and its own ancillary services.
The coding and billing standards body whose credentials most billers and coders hold.
Enforcement guidance on billing compliance, and the arrangements that attract scrutiny.
The procedure-to-procedure and medically unlikely edits behind most bundling denials.
The specialty society behind chemotherapy administration and J-code drug guidance.
Your hem-onc practice deserves billing partners who know the chemo administration hierarchy, J-code waste reporting with JW, and clinical trial Q0/Q1 modifiers — and code every claim correctly. Let MedFactor show you what specialty RCM can do.
Request Free Billing Audit
Explore Services
HIPAA Compliant
AAPC Certified
Nationwide Support